Science

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

Sergio Cifuentes Canabal/LinkedIn

Mar 3, 2025, 11:35

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

Sergio Cifuentes, Cancer Research Project Manager at CENEIT Mexico, shared a post on X about a paper by Mohamed Gouda et al. published in Clinical Cancer Research:

“Resistance to T-DXd:

HER2 loss: 32.4%
HER2 decrease expression: 29.4%

Reevaluation of HER2 status following T-DXd treatment should be considered prior to alternate HER2-targeted therapies.”

“Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer”

Authors: Mohamed Gouda, Amrit Gonugunta, Ecaterina Dumbrava, Hui Chen, Funda Meric-Bernstam et al.

Sergio Cifuentes: Reevaluation of HER2 status following T-DXd treatment

More posts featuring Sergio Cifuentes.

Amrit Gonugunta Breast Cancer cancer Ecaterina Dumbrava Funda Meric-Bernstam Hui Chen Mohamed Gouda OncoDaily Oncology Sergio Cifuentes Trastuzumab deruxtecan

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience